%0 Journal Article
%T Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification
%A Bo Zhang
%A Chunguo Wang
%A Dehua Ma
%A Feng Xu
%A Francesco Grossi
%A Hideharu Kimura
%A Jian Zhang
%A Jianfei Shen
%A Jiang Jin
%A Kenichi Suda
%A Linna Zhang
%A Luca Ampollini
%A Paul van Schil
%A written on behalf of the AME Lung Cancer Collaborative Group
%J SCIE-indexed Journal
%D 2018
%R 10.21037/jtd.2018.10.55
%X In the past, the optimal first-line treatment of advanced non-small cell lung cancer (NSCLC) patients with wild-type for epidermal growth factor receptor (wt-EGFR) has been platinum-based chemotherapy doublets (1,2). More recently, clinicians have adopted immunotherapy with check-point inhibitors alone, in PD-L1 strong positive, or combined with chemotherapy independently to PD-L1 expression (3). In the second-line, for wt-EGFR patients, tyrosine kinase inhibitors (TKIs) have been considered, albeit controversially, as a potential treatment option (4,5). Several studies have shown that EGFR gene copy number or amplification detected by fluorescence in situ hybridization (FISH) could be a good biomarker for predicting treatment response to EGFR TKIs in patients with advanced NSCLC (6-8). Here we reported a successful experience with a patient with lung adenocarcinoma wt-EGFR and EGFR gene amplification who received benefit from gefitinib treatment
%U http://jtd.amegroups.com/article/view/24888/html